TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2074253
Drug: Cefodizime 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 1.0 g
Study: 2074253
Drug: Cefodizime 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 2.0 g
Study: 8540712
Drug: Cefodizime 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 3.0 g
Study: 1571381
Drug: Cefodizime (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (all doses)
Study: 6794746
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin injection (20 U of regular insulin) into an empty peritoneal cavity
Study: 6794746
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin injection (20 U of regular insulin) followed by 2 litres of 4.5% dextrose dialysate
Study: 6794746
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin injection (20 U of regular insulin) followed by 20 ml of saline
Study: 11717214
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol anesthesia (n = 6)
Study: 9159421
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of gynaecological disorders including measurement of hormone concentrations, cervical cytology, and pelvic ultrasound scan.
Study: 29641671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with tramadol hydrochloride injection
Study: 12818266
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for up to 12 months
Study: 12818266
Drug: Esomeprazole 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40, 20, or 10 mg daily for up to 6 months
Study: 8992517
Drug: Flupentixol (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol (exact dosage and duration not specified)
Study: 6362698
Drug: Flunitrazepam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (2.0 mg)
Study: 30804065
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted serum calcium concentrations (increase of 0.5 mg/dL)
Study: 18591543
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy for 90 days, consisting of 14-day cycles followed by 3-day higher doses.
Study: 7640501
Drug: Fungus Lipid‐reducing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungus Lipid‐reducing Capsule (FLC) treated group
Study: 2860283
Drug: Temazepam 20
Normalized name: temazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 20 mg in uncoated tablet
Study: 18426844
Drug: Praneem polyherbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praneem polyherbal vaginal tablet
Study: 11716075
Drug: 1% chlorhexidine/methylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine/methylcellulose gel (group C)
Study: 11716075
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (no medication)
Study: 2291751
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen 550 mg every 12 h
Study: 2291751
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac 100 mg every 12 h
Study: 31101682
Drug: best standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: best standard therapy (BST)
Study: 28383414
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (5% lidocaine and 25 mg/g prilocaine, 5g applied preoperatively)
Study: 19056445
Drug: Telephone recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone recall system managed by pediatricians from asthma clinic with vaccine administered in the same clinic (group 3)
Study: 11408210
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 5 mg/kg daily and rifampin (RIF) 10 mg/kg daily
Study: 11408210
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 5 mg/kg daily plus 10 mg of rifalazil once weekly
Study: 9495409
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg intrathecal morphine plus 75 mg i.m. diclofenac every 8 h
Study: 9495409
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg intrathecal morphine plus i.m. diclofenac on demand
Study: 9495409
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg intrathecal morphine plus i.m. diclofenac on demand
Study: 3053587
Drug: Carbohydrate feeding
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate feeding (1 g/kg at 10 min, then 0.6 g/kg every 30 min)
Study: 31902925
Drug: DT algorithm
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DT algorithm for initial dose settings of VCM
Study: 31902925
Drug: Conventional dose-setting
Normalized name: DRESSING,WET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose-setting methods
Study: 28287490
Drug: Vitamin B12-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12-containing multiple micronutrient supplement
Study: 21984924
Drug: gp140 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp140 vaccine (100 µg in 3 ml of Carbopol 974P based gel)
Study: 21984924
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution in Carbopol gel
Study: 18224343
Drug: Mizoribine combination
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine combination therapy
Study: 20674417
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg metoclopramide
Study: 14633536
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg droperidol
Study: 14633536
Drug: 0.13 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.13 mg/kg ondansetron
Study: 20395895
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL saline
Study: 14633536
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg metoclopramide
Study: 1485367
Drug: 300 or
Normalized name: Xodol 5/300 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 or 600 mg of racemic ibuprofen (chronic dosing)
Study: 20461028
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg once daily for the first 7 weeks, increased to 120 mg for those with <30% pain reduction at week 7)
Study: 12752317
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg bid everolimus
Study: 12752317
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg bid everolimus
Study: 7408407
Drug: Oral bretylium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bretylium tosylate (5 mg/kg)
Study: 7408407
Drug: Intravenous bretylium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bretylium tosylate (5 mg/kg)
Study: 27296626
Drug: 15-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15-week oral language programme delivered by trained teaching assistants
Study: 21816640
Drug: Low-dose ATN-224
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATN-224 (30 mg daily)
Study: 21816640
Drug: High-dose ATN-224
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATN-224 (300 mg daily)
Study: 21640687
Drug: Bedtime cilnidipine
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime cilnidipine (10-20 mg/day)
Study: 12657911
Drug: Racemic reboxetine
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic reboxetine (6-month monotherapy)
Study: 4050068
Drug: Aspirin-dipyridamole (ASA-D)
Normalized name: aspirin / dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-dipyridamole (ASA-D)
Study: 4050068
Drug: Anticoagulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation with coumadine preparations (AC)
Study: 31880109
Drug: Critical care
Normalized name: Adult critical care formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical care ultrasound oriented treatment
Study: 24591296
Drug: Nasal douche
Normalized name: Alkalol Nasal Douche Cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal douche containing 9 mg of high molecular weight sodium hyaluronate plus saline solution
Study: 24591296
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution alone
Study: 22137609
Drug: Integrated pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Integrated pharmaceutical care programme (IPCP)
Study: 6395920
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Subgroup O)
Study: 6395920
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Tamoxifen (Subgroup N)
Study: 6395920
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Tamoxifen + Norethisterone (Subgroup NN)
Study: 6395920
Drug: Chemotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Group I)
Study: 17211866
Drug: IA carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IA carboplatin with intravenous etoposide and cyclophosphamide
Study: 17211866
Drug: IA methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IA methotrexate with intravenous etoposide and cyclophosphamide
Study: 12171809
Drug: Nortriptyline, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline, 75 mg/d for 6 weeks
Study: 7758327
Drug: Histamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.1 mg/ml) administered via subcutaneous injections or by scratching at the site of patch tests
Study: 1869364
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg x 3 days
Study: 1869364
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg x 2 days
Study: 1869364
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg x 1 day
Study: 15641626
Drug: Once-daily budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily budesonide administration
Study: 7707626
Drug: Monovalent vaccine
Normalized name: rotavirus, live, monovalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccine
Study: 7704169
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine
Study: 28340572
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg, maximum 20 mg) and oral ketamine (3 mg/kg, maximum 50 mg) with 100% oxygen (MK)
Study: 28340572
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg, maximum 20 mg) and oral ketamine (3 mg/kg, maximum 50 mg) with inhalational sevoflurane at a sedative dose (MKS)
Study: 23109026
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of normal saline via intravenous route)
Study: 17405800
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVTA) injections
Study: 15082356
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intranasal (PCIN) fentanyl
Study: 22268365
Drug: Irbesartan 600
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 600 mg
Study: 22268365
Drug: Irbesartan 900
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 900 mg
Study: 26115880
Drug: LITE condition
Normalized name: Lite 'N Foamy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LITE condition (one tai chi session twice weekly for 12 weeks)
Study: 26115880
Drug: PLUS condition
Normalized name: Dermarest Psoriasis Shampoo Plus Conditioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLUS condition (one tai chi session 3 times weekly for 12 weeks, followed by maintenance classes 1-2 times weekly for an additional 12 weeks)
Study: 24586994
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of rosuvastatin
Study: 16950182
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of atorvastatin
Study: 8339135
Drug: Intermittent D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent D-penicillamine therapy (250-750mg daily reduced to the same dose taken 1 week out of every 4)
Study: 8339135
Drug: Continuous D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous D-penicillamine therapy
Study: 3522630
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral self-control therapy (adjunctive therapy)
Study: 3522630
Drug: Stimulant medications
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medications (standard treatment)
Study: 29901369
Drug: DMPA (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA (150 mg injections)
Study: 29901369
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no DMPA injection)
Study: 16410276
Drug: Modified intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intensified insulin therapy (MII) using insulin pens and premixed insulin (30/70, 40/60, 50/50) in Group AI and Group AII.
Study: 16410276
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy in Group B.
Study: 12838216
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg) administered orally 15 hours and 3 hours before ERCP
Study: 28233458
Drug: β-blocker treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker treatment
Study: 11447078
Drug: 450 mL
Normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mL black tea
Study: 11447078
Drug: 900 mL
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mL black tea daily for 4 weeks
Study: 9508353
Drug: Intravenous Ferrum
Normalized name: Ferrum
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ferrum Hausmann (iron dextrin)
Study: 8293316
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg tyrosine
Study: 31978591
Drug: Hydrogel rectal
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel rectal spacer
Study: 26022239
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine
Study: 21689356
Drug: Preoperative mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative mechanical bowel preparation (4 l of polyethylene glycol) plus a glycerine 5% enema (2 l)
Study: 21689356
Drug: Single glycerine
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single glycerine 5% enema (2 l)
Study: 18087660
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg risedronate on two consecutive days each month (2CDM)
Study: 18087660
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg daily risedronate
Study: 17078437
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at the Back‐Shu and Front‐Mu points plus oral decoction
Study: 17078437
Drug: Oral decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decoction alone
Study: 30106253
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram
Study: 15274173
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg escitalopram
Study: 15274173
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (5 mg, 10 mg, 20 mg escitalopram and 20 mg paroxetine)
Study: 15274173
Drug: Escitalopram (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (5-20 mg)
Study: 11400897
Drug: High-energy extracorporeal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy extracorporeal shock wave therapy (Group II)
Study: 9003206
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 micrograms twice daily
Study: 2892258
Drug: nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 150 mg B.D.
Study: 19591515
Drug: Clozapine ODT
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine ODT 12.5 mg administered after a high-fat/calorie breakfast
Study: 19591515
Drug: Clozapine ODT
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine ODT 12.5 mg administered in a fasted state
Study: 14566480
Drug: Moist skin
Normalized name: Moist Skin 12% Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist skin care with 3% urea lotion
Study: 29035942
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with bilateral application of diagnostic levels of ultrasound energy
Study: 8305322
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied twice daily
Study: 3194866
Drug: Prednisone 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 12.5 mg daily
Study: 25906818
Drug: Sodium-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-restricted diet (maximum intake of 3 g of sodium per day)
Study: 25906818
Drug: Diuretic (spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (spironolactone plus furosemide)
Study: 22803688
Drug: GSK2190915 (50-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 (50-1000 mg single doses; 10-450 mg multiple doses; 10-200 mg in crossover design)
Study: 22803688
Drug: GSK2190915 (≥50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 (≥50 mg)
Study: 22803688
Drug: GSK2190915 (≥150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 (≥150 mg)
Study: 18289576
Drug: 100 to
Normalized name: Zionodil 100 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 to 120 mg bacillus Calmette‐Guerin alone
Study: 16688994
Drug: Medopa orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medopa orally, 125 mg 3 times/day for mild, 250 mg 3 times/day for moderate, and 250 mg 4 times/day for severe cases, for 6 weeks.
Study: 9797484
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/day (RLX120)
Study: 9797484
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (RLX60)
Study: 1382915
Drug: Lysine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine infusion (3-6 g of lysine intravenously followed by 0.3-1.9 g of lysine/kg over 1 hour)
Study: 18035202
Drug: IM IFN‐betala
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM IFN‐betala 30 microg QW (low-dose)
Study: 18035202
Drug: SC IFN‐beta1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC IFN‐beta1a 44 microg TIW (high-dose)
Study: 16253344
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (500-2500 mg/day)
Study: 26137537
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate
Study: 10078713
Drug: Eptastigmine 15
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 15 mg three times daily
Study: 10078713
Drug: Eptastigmine 20
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 20 mg three times daily
Study: 8545144
Drug: Ibuprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (3 x 400 mg)
Study: 8545144
Drug: Ibuprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (3 x 400 mg and 3 x 800 mg)
Study: 10155349
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg once daily)
Study: 1974509
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg twice daily)
Study: 6112925
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 g cephaloridine injected intravenously at the start of operations
Study: 6112925
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 g cephaloridine instilled into the incision at the end of operations
Study: 27208499
Drug: Propofol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.8 mg/kg)
Study: 29070709
Drug: NP-BEEF diet
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP-BEEF diet (48 g protein/d)